Cargando…

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC

The study was performed to investigate the antitumor efficacy of histone deacetylase inhibitor (HDACi) chidamide alone or with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) icotinib in non-small cell lung cancer (NSCLC). The cell viability, cell cycle, apoptosis, protein expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ningning, Liang, Caixia, Song, Wenya, Tao, Dan, Yao, Jiarui, Wang, Shuai, Ma, Li, Shi, Yuankai, Han, Xiaohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400687/ https://www.ncbi.nlm.nih.gov/pubmed/30854137 http://dx.doi.org/10.7150/jca.28570

Ejemplares similares

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2016)

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma
por: Wen, Tingyu, et al.
Publicado: (2022)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
por: Yao, Yushi, et al.
Publicado: (2013)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF-κB pathway in multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2019)

Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner
por: Yuan, Xiang-Gui, et al.
Publicado: (2019)

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
por: Zhang, Na, et al.
Publicado: (2020)

Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model
por: Tan, Jianlong, et al.
Publicado: (2017)

Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2018)

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL
por: Wei, Chong, et al.
Publicado: (2021)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020)

Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer
por: Liu, Bing, et al.
Publicado: (2016)

A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy
por: ZHENG, XIAO, et al.
Publicado: (2014)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with l-phenylglycine scaffold
por: Zhang, Yingjie, et al.
Publicado: (2015)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
por: Xu, Jianping, et al.
Publicado: (2017)

Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor Xenografts
por: Wang, Shuai, et al.
Publicado: (2014)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

Interferon Regulatory Factor-8 Is Important for Histone Deacetylase Inhibitor-Mediated Antitumor Activity
por: Banik, Debarati, et al.
Publicado: (2012)

Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer()
por: Zhang, Tao, et al.
Publicado: (2014)

Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824
por: Mei, Qinglang, et al.
Publicado: (2023)

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide
por: Fu, Hua-Rui, et al.
Publicado: (2021)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
por: Wu, Zhen, et al.
Publicado: (2019)

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)
por: Zhu, Qianqian, et al.
Publicado: (2017)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
por: Paller, Channing J, et al.
Publicado: (2014)

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells
por: Gueugnon, Fabien, et al.
Publicado: (2014)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
por: Xu, Jianping, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
por: Mao, Long-fei, et al.
Publicado: (2020)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Chen, Qi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5k76v2qpv7a2n1nhdin9ku7796